Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Prednisolone reduces nitric oxide-induced migraine

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Ocrelizumab treatment in multiple sclerosis: A Danish population-based cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Hospital readmissions following infections in dementia: a nationwide and registry-based cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. European guideline and expert statements on the management of narcolepsy in adults and children

    Research output: Contribution to journalReviewResearchpeer-review

  4. Muscle involvement assessed by quantitative magnetic resonance imaging in patients with anoctamin 5 deficiency

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Guidelines should be guidelines: Time to leave the terms "consensus" and "position" for other purposes

    Research output: Contribution to journalEditorialResearchpeer-review

  1. Vestibular migraine: diagnostic criteria1

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. CGRP-dependent signalling pathways involved in mouse models of GTN- cilostazol- and levcromakalim-induced migraine

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Naratriptan is as effective as sumatriptan for the treatment of migraine attacks when used properly. A mini-review

    Research output: Contribution to journalReviewResearchpeer-review

View graph of relations
BACKGROUND AND PURPOSE: Glyceryl trinitrate (GTN) induces delayed migraine attacks in migraine patients. The purpose of this study was to investigate whether pre-treatment with prednisolon could decrease this effect of GTN. METHODS: In this double-blind, randomized and placebo-controlled, crossover study 15 migraineurs with migraine without aura were pre-treated with 150 mg of prednisolone or placebo followed by a 20-min infusion of GTN (0.5 ug/kg/min). One hour after the GTN-infusion, the participants were sent home, but continued to rate headache and possible associated symptoms by filling out a headache diary every hour for 12 h. There were two equal primary efficacy end-points: frequency of delayed migraine and intensity of delayed headache. RESULTS: Nine patients experienced a GTN headache fulfilling the diagnostic criteria for migraine without aura on the placebo day compared with four patients on the prednisolone day (P = 0.14). Prednisolone pre-treatment did not alter the summed or peak immediate headache responses to GTN significantly (P = 0.08, P = 0.07), whereas the peak headache scores during the following 12 h were significantly lower after prednisolone pre-treatment (median peak score = 1, range 0-8) compared with placebo (median = 4, range 0-8) (P < 0.01). There was no difference between the two treatment days in the effect of GTN on blood flow velocity of the middle cerebral artery (a decrease) or on the dilation of the superficial temporal artery or the radial artery. CONCLUSION: Pre-treatment with prednisolone did not reduce the immediate GTN-induced headache, did not inhibit the frequency of delayed headache but significantly decreased the intensity of delayed GTN-induced headache. These findings suggest that GTN causes induction of inflammatory mediators, and that this is the mechanism of delayed GTN-induced migraine. They also support a role of inflammatory mediators in spontaneous migraine attacks.
Original languageEnglish
JournalEuropean Journal of Neurology
Volume16
Issue number10
Pages (from-to)1106-11
Number of pages5
ISSN1351-5101
DOIs
Publication statusPublished - 2009

Bibliographical note

Keywords: Adult; Analysis of Variance; Blood Flow Velocity; Cerebrovascular Circulation; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Middle Aged; Migraine without Aura; Nitroglycerin; Pain Measurement; Prednisolone; Severity of Illness Index

ID: 172605